To explicate the lipid metabolic basis underlying the anti-NAFLD-HCC effects of Sphk2-KO, we examined lipid changes in non-tumorous liver tissues using lipidomics. This evidence concerns the gene SPHK2 and metabolic dysfunction-associated steatotic liver disease.